Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa.

Mac Kenzie WR, Heilig CM, Bozeman L, Johnson JL, Muzanye G, Dunbar D, Jost KC Jr, Diem L, Metchock B, Eisenach K, Dorman S, Goldberg S.

PLoS One. 2011 Apr 11;6(4):e18358. doi: 10.1371/journal.pone.0018358.

2.

Immunological biomarkers of tuberculosis.

Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A.

Nat Rev Immunol. 2011 May;11(5):343-54. doi: 10.1038/nri2960. Epub 2011 Apr 8. Review.

PMID:
21475309
3.

Global tuberculosis drug development pipeline: the need and the reality.

Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X.

Lancet. 2010 Jun 12;375(9731):2100-9. doi: 10.1016/S0140-6736(10)60359-9. Epub 2010 May 18. Review.

PMID:
20488518
4.

Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice.

Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, Zumla A.

Lancet. 2010 May 29;375(9729):1920-37. doi: 10.1016/S0140-6736(10)60359-5. Epub 2010 May 18. Review.

PMID:
20488517
5.

Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity.

Davies GR.

Tuberculosis (Edinb). 2010 May;90(3):171-6. doi: 10.1016/j.tube.2010.03.007. Epub 2010 Apr 10. Review.

PMID:
20382567
6.
7.

Timing of relapse in short-course chemotherapy trials for tuberculosis.

Nunn AJ, Phillips PP, Mitchison DA.

Int J Tuberc Lung Dis. 2010 Feb;14(2):241-2.

PMID:
20074418
8.

Biomarkers of disease activity, cure, and relapse in tuberculosis.

Doherty TM, Wallis RS, Zumla A.

Clin Chest Med. 2009 Dec;30(4):783-96, x. doi: 10.1016/j.ccm.2009.08.008. Review.

PMID:
19925967
9.

Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods.

Green C, Huggett JF, Talbot E, Mwaba P, Reither K, Zumla AI.

Lancet Infect Dis. 2009 Aug;9(8):505-11. doi: 10.1016/S1473-3099(09)70149-5. Review. Erratum in: Lancet Infect Dis. 2009 Sep;9(9):536.

PMID:
19628175
10.

Biomarkers for tuberculosis disease activity, cure, and relapse.

Wallis RS, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A.

Lancet Infect Dis. 2009 Mar;9(3):162-72. doi: 10.1016/S1473-3099(09)70042-8. Review.

PMID:
19246020
11.

Surrogate and mediating endpoints: current status and future directions.

Prentice RL.

J Natl Cancer Inst. 2009 Feb 18;101(4):216-7. doi: 10.1093/jnci/djn515. Epub 2009 Feb 10. No abstract available.

PMID:
19211455
12.

Using animal models to develop new treatments for tuberculosis.

Nuermberger E.

Semin Respir Crit Care Med. 2008 Oct;29(5):542-51. doi: 10.1055/s-0028-1085705. Epub 2008 Sep 22. Review.

PMID:
18810687
13.

Banking of biological fluids for studies of disease-associated protein biomarkers.

Schrohl AS, Würtz S, Kohn E, Banks RE, Nielsen HJ, Sweep FC, Brünner N.

Mol Cell Proteomics. 2008 Oct;7(10):2061-6. doi: 10.1074/mcp.R800010-MCP200. Epub 2008 Aug 1. Review.

14.

Biomarkers for TB treatment response: challenges and future strategies.

Walzl G, Ronacher K, Djoba Siawaya JF, Dockrell HM.

J Infect. 2008 Aug;57(2):103-9. doi: 10.1016/j.jinf.2008.06.007. Epub 2008 Jul 22. Review.

PMID:
18649943
15.

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H; Protocol 004 Part II Study Team.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):125-33.

PMID:
17721395
16.

Biomarkers and surrogate end points in clinical trials of tuberculosis treatment.

Davies GR, Phillips PP, Nunn AJ.

J Infect Dis. 2007 Aug 15;196(4):648-9; author reply 649-50. No abstract available.

PMID:
17624855
17.

Biomarkers of treatment response in clinical trials of novel antituberculosis agents.

Perrin FM, Lipman MC, McHugh TD, Gillespie SH.

Lancet Infect Dis. 2007 Jul;7(7):481-90. Review.

PMID:
17524807
18.

Tuberculosis drug development pipeline: progress and hope.

Spigelman M, Gillespie S.

Lancet. 2006 Mar 18;367(9514):945-7. No abstract available.

PMID:
16546546
19.

Recurrent tuberculosis in the United States and Canada: relapse or reinfection?

Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, Khan A, Burman WJ; Tuberculosis Trials Consortium.

Am J Respir Crit Care Med. 2004 Dec 15;170(12):1360-6. Epub 2004 Oct 11.

PMID:
15477492
20.

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society.

Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62. No abstract available.

PMID:
12588714

Supplemental Content

Support Center